Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Edward Hospital

Neither a doctor nor a teaching hospital

Research payments

$271,164

31 payments

Through program year 2025, Edward Hospital is reported as receiving $271,164 in research payments, across 31 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $4,220 4
2024 Research $57,210 6
2023 Research $116,127 7
2022 Research $7,841 6
2021 Research $17,446 4
2020 Research $59,272 3
2019 Research $9,049 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. Daiichi Sankyo Inc. $122,920 10 payments
  2. Abbott Laboratories $51,519 1 payment
  3. Medtronic, Inc. $50,000 1 payment
  4. Ipsen Bioscience Inc $16,414 3 payments
  5. Novartis Pharmaceuticals Corporation $16,129 4 payments
  6. Genentech, Inc. $7,977 11 payments
  7. AstraZeneca Pharmaceuticals LP $6,206 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Ds8201-A-U305 $122,920 10 payments
  2. AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial $51,519 1 payment
  3. Cydar Aortic Pilot Program $50,000 1 payment
  4. An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas $15,464 2 payments
  5. Solar1 A Phase III Randomized Double Blind Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive Her2 Negative Advanced Breast Cancer Which Progressed on Or After Aromatase in $9,049 1 payment
  6. Chemo Trastuzumab VS Chemo Trastuzumab Pertuzumab $7,977 11 payments
  7. A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) $6,206 1 payment
  8. A Randomized Double Blind Placebo Controlled Study of Lee011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive Her2 Negative Advanced Breast Cancer Who Received No Prior Hormonal Therapy for Advanced Di $6,048 2 payments
  9. A Randomized Double Blind Placebo Controlled Study of Lee011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive Her2 Negative Advanced Breast Cancer Who Received No Prior Hormonal Therapy for Advanced Disease $1,032 1 payment
  10. An Open-label Randomised Multicentre Phase III Study of Irinotecan Liposome Injection Oxaliplatin 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas $950 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record